Eli Lilly and Company

Other

Behringwerke Aktiengesellschaft

Beiersdorf-lilly Gmbh

Beiersdorf Ag

Paal, Michael

Kolar, Cenek

Hermentin, Peter

Kraemer, Hans P.

Michael Paal

Wolfgang Stenzel

Theo Schotten

Matthew Joseph Fisher

Joseph A Jakubowski

Gerd Ruhter

Kenneth James Ruterbories

Gerd R Uhter

Robert M Scarborough

Daniel Jon Sall

Michael J Martinelli

John Joseph Masters

John Michael Morin, Jr

Cenek Kolar

Michael Dean Kinnick

Peter Hermentin

Hans P Kraemer

Robert Theodore Vasileff

Jeffrey Thomas Mullaney

Allen D Kline

Anne Marie Happ

Marshall A Skelton

William F Heath, Jr

John H McDonald, Iii

Dieter Hoffmann

Hans G Berscheid

Dirk Bottger

Chuan Shih

Michael R Jirousek

Kumiko Takeuchi

Sajan Joseph

Guoxin Zhu

James E Ray

Ben Armah

Manfred Gerken

Tiechao Li

Philip Parker Waid

Radhakrishnan Rathnachalam

Jianping Huang

Rima Salim Al-Awar

Kyle Andrew Hecker

Gerd R&uuml;hter

Reinhard Bruckner

Xun Zhou

Hans Peter Kraemer

Hans Gerd Berscheid

William Francis Heath Junior Heath

John Hampton Iii Mcdonald

Schotten Theo

The present invention provides selective kinase inhibitors of formula (I)

Agents and methods for the treatment of proliferative diseases

This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation

This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Glycoprotein IIb/IIIa antagonists

This invention relates to certain novel imidazoline compounds and analogues thereof, to their use for the treatment of diabetes, diabetic complications, metabolic disorders, or related diseases where impaired glucose disposal is present, to pharmaceutical compositions comprising them, and to processes for their preparation.

Hypoglycemic imidazoline compounds

This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I):

Glycoprotein IIB IIIA antagonists

The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.

Protein kinase C inhibitors

Compounds for treating cardiovascular or circulatory disorders of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.7, Ar.sup.1, Ar.sup.2, X, Y, and n are defined herein.

Pyrimidine compounds and their use as pharmaceuticals

Compounds having the formula ##STR1## and the other variables are as defined herein, and are indicated for use in the treatment and prophylaxis of, for example, hypertension, congestive heart failure, ocular hypertension, renal failure, and CNS disorders, or are intermediates thereto.

Pharmaceutical compounds which are azolo-fused pyrimidine compounds having the formula ##STR1## in which .dbd.A--B-- together with the pyrimidine ring forms a) a pyrazolo[1,5-a]pyrimidine of formula (A), ##STR2## b) a [1,2,4]triazolo[1,5-a]pyrimidine of formula (B), ##STR3## c) an imidazo[1,5-a]pyrimidine of formula (C), ##STR4## or d) an imidazo[1,2-a]pyrimidine of formula (D), ##STR5##

Fused pyrimidine compounds and their use as pharmaceuticals

The present invention discloses compounds of the general formula: ##STR1## The compounds are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.

Compounds for the treatment of cardiac insufficiency, an arterial thrombo embolism, an arterial occlusive disease, psoriasis, neurodermatitis, asthma, platelet aggregation and hypertension, of the formula ##STR1## in which R.sub.1 is hydrogen, C.sub.1-6 -alkyl, C.sub.2-6 -alkenyl or C.sub.3-7 -cycloalkyl,

Cardioactive pyrrolobenzimidazoles

The invention relates to new anthracycline derivatives having cytostatic activity and the general formula I ##STR1## wherein R.sup.1 is a CH.sub.3 (CH.sub.2).sub.n group with n=0 to 3,

Anthracycline derivatives having cytostatic activity

Growing community of inventors

Hamburg, Germany

Michael Paal